| REVENUE RECOGNITION The following is a summary of our net sales by category (in millions): | | | | | | | | | | | | | | | | | | | | | | | | | Three Months Ended | | Six Months Ended | | June 28, 2025 | | June 29, 2024 | | June 28, 2025 | | June 29, 2024 | CSCA | | | | | | | | | Upper Respiratory | $ | 123.3 | | | $ | 118.8 | | | $ | 261.2 | | | $ | 249.1 | | | Digestive Health | 109.7 | | | 126.0 | | | 212.7 | | | 248.2 | | | Nutrition | 95.6 | | | 86.1 | | | 200.3 | | | 176.7 | | | Pain and Sleep-Aids | 80.2 | | | 81.6 | | | 156.8 | | | 164.2 | | | Healthy Lifestyle | 73.7 | | | 69.1 | | | 144.1 | | | 140.4 | | | Oral Care | 60.0 | | | 73.2 | | | 122.0 | | | 137.9 | | | Skin Care | 57.8 | | | 57.1 | | | 106.3 | | | 106.7 | | | Women's Health | 18.7 | | | 16.8 | | | 33.7 | | | 44.0 | | | Vitamins, Minerals, and Supplements ("VMS") | 2.1 | | | 5.3 | | | 3.8 | | | 9.5 | | Other CSCA(1) | 0.9 | | | 0.1 | | | 1.8 | | | 1.6 | | | Total CSCA | $ | 622.0 | | | $ | 634.1 | | | $ | 1,242.8 | | | $ | 1,278.3 | | | CSCI | | | | | | | | | Skin Care | $ | 122.9 | | | $ | 127.7 | | | $ | 234.4 | | | $ | 242.4 | | | Pain and Sleep-Aids | 63.5 | | | 50.3 | | | 117.1 | | | 101.7 | | | Healthy Lifestyle | 60.7 | | | 57.5 | | | 127.3 | | | 122.1 | | | Upper Respiratory | 55.4 | | | 50.7 | | | 128.9 | | | 119.8 | | | Women's Health | 41.1 | | | 36.9 | | | 73.5 | | | 68.9 | | | VMS | 38.6 | | | 39.9 | | | 76.2 | | | 84.5 | | | Oral Care | 25.2 | | | 23.0 | | | 47.7 | | | 51.7 | | | Digestive Health | 9.9 | | | 8.5 | | | 19.5 | | | 18.0 | | Other CSCI(1) | 16.9 | | | 36.8 | | | 32.8 | | | 60.1 | | | Total CSCI | $ | 434.3 | | | $ | 431.3 | | | $ | 857.4 | | | $ | 869.3 | | | | | | | | | | | Total net sales | $ | 1,056.3 | | | $ | 1,065.5 | | | $ | 2,100.2 | | | $ | 2,147.5 | |
(1) Consists primarily of other miscellaneous or otherwise uncategorized product lines, none of which is greater than 10% of the segment net sales.
The following table provides information about contract assets from contracts with customers (in millions): | | | | | | | | | | | | | | | | | | | Balance Sheet Location | | June 28, 2025 | | December 31, 2024 | | Short-term contract assets | Prepaid expenses and other current assets | | $ | 28.4 | | | $ | 43.9 | |
We generated net sales in the following geographic locations(1) (in millions): | | | | | | | | | | | | | | | | | | | | | | | | | Three Months Ended | | Six Months Ended | | June 28, 2025 | | June 29, 2024 | | June 28, 2025 | | June 29, 2024 | | U.S. | $ | 610.9 | | | $ | 627.8 | | | $ | 1,220.2 | | | $ | 1,260.1 | | Europe(2) | 421.7 | | | 408.4 | | | 833.9 | | | 828.1 | | All other countries(3) | 23.7 | | | 29.3 | | | 46.1 | | | 59.3 | | | Total net sales | $ | 1,056.3 | | | $ | 1,065.5 | | | $ | 2,100.2 | | | $ | 2,147.5 | |
(1) The net sales by geography are derived from the location of the entity that sells to a third party. (2) Includes Ireland net sales of $9.8 million and $20.8 million for the three and six months ended June 28, 2025, and $11.4 million and $15.7 million for the three and six months ended June 29, 2024. (3) Includes net sales generated primarily in Australia and Canada.
|